Last reviewed · How we verify

NCT04014400: Suprathel

Suprathel Versus Xeroform for the Management of Skin Graft Donor Sites

Terminated NA Last updated 22 October 2020
What this trial tests

NA trial testing Suprathel or Xeroform donor site application in Burns in 10 participants. Terminated before completion.

Timeline
7 July 2019
Primary endpoint
23 July 2020
23 July 2020

Quick facts

Lead sponsorUniversity of Colorado, Denver
PhaseNA
StatusTerminated
Study typeINTERVENTIONAL
Allocationrandomized
Designparallel
Maskingsingle
Primary purposetreatment
Enrollment10
Start date7 July 2019
Primary completion23 July 2020
Estimated completion23 July 2020
Sites2 locations across United States

Drugs / interventions tested

Conditions studied

Sponsor

University of Colorado, Denver

Who can join

Adults 31 Days to 80, any sex, with Burns or Skin Graft Complications. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The investigators aim to study whether Suprathel, a synthetic temporary skin substitute developed by PolyMedics Innovations GmBH aids in the management of patient pain and wound healing when compared to the current standard dressing used of a primary Xeroform dressing.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Burns

Currently open trials in the same condition.

Other University of Colorado, Denver trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04014400.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing